References
- Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 2019; 71: 104–14. doi: 10.1016/j.jhep.2019.03.013
- Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet 2021; 397: 428–44. doi: 10.1016/S0140-6736(21)00153-7
- Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, et al; ESMO Guidelines Committee. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 127–40. doi: 10.1016/j.annonc.2022.10.506
- National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Biliary tract cancers. V 3. [online]. 2023. [cited 2024 Feb 18]. Available at:
https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf - Cancer in Slovenia 2020. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2023.
- Đokic M, Stupan U, Licen S, Trotovsek B. Residual disease in lymph nodes has no influence on survival in patients with incidental gallbladder cancer − institution experience with literature review. Radiol Oncol 2021; 56: 208–15. doi: 10.2478/raon-2021-0048
- Fostea RM, Fontana E, Torga G, Arkenau HT. Recent progress in the systemic treatment of advanced/metastatic cholangiocarcinoma. Cancers 2020; 12: 2599. doi: 10.3390/cancers12092599
- Mirallas O, López-Valbuena D, García-Illescas D, Fabregat-Franco C, Verdaguer H, Tabernero, et al. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. ESMO Open 2022;7: 100503. doi: 10.1016/j.esmoop.2022.100503
- Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273–81. doi: 10.1056/NEJMoa0908721
- Oh DY, He AR, Qin S, Chen T, Okusaka T, Arndt Vogel, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1: EVID 0a2200015. doi: 10.1056/EVIDoa2200015
- Ferreira CR, Gahl WA. Disorders of metal metabolism. Transl Sci Rare Dis 2017; 2: 101–39. doi: 10.3233/TRD-170015
- Morales M, Xue X. Targeting iron metabolism in cancer therapy. Theranostics 2021; 11: 8412–29. doi: 10.7150/thno.59092
- Stojsavljević, A, Vujotić L, Rovčanin B, Borković-Mitić S, Gavrović-Jankulović, Manojlović D. Assessment of trace metal alterations in the blood, cerebrospinal fluid and tissue samples of patients with malignant brain tumors. Sci Rep 2020; 10: 3816. doi: 10.1038/s41598-020-60774-0
- Lelièvre P, Sancey L, Coll JL, Deniaud A, Busser B. The multifaceted roles of copper in cancer: A trace metal element with dysregulated metabolism, but also a target or a bullet for therapy. Cancers 2020; 12: 3594. doi: 10.3390/cancers12123594
- Chen F, Han B, Meng Y, Han Y, Liu B, Zhang B, et al. Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer. Aging 2021; 13: 20438–67. doi: 10.18632/aging.203427
- Wang B, Wang XP. Does ceruloplasmin defend against neurodegenerative diseases? Curr Neuropharmacol 2019; 17: 539–49. doi: 10.2174/1570159X16666180508113025
- Linder MC. Ceruloplasmin and other copper binding components of blood plasma and their functions: an update. Metallomics 2016; 8: 887–905. doi: 10.1039/c6mt00103c
- Mukae Y, Ito H, Miyata Y, Araki K, Matsuda T, Aibara N, et al. Ceruloplasmin levels in cancer tissues and urine are significant biomarkers of pathological features and outcome in bladder cancer. Anticancer Res 2021; 41: 3815–23. doi: 10.21873/anticanres.15174
- Sogabe M, Kojima S, Kaya T, Tomioka A, Kaji H, Sato T, et al. Sensitive new assay system for serum wisteria floribunda agglutinin-reactive ceruloplasmin that distinguishes ovarian clear cell carcinoma from endometrioma. Anal Chem 2022; 94: 2476–84. doi: 10.1021/acs.analchem.1c04302
- Michalczyk K, Cymbaluk-Płoska A. The role of zinc and copper in gynecological malignancies. Nutrients 2020; 12: 3732. doi: 10.3390/nu12123732
- Woimant F, Djebrani-Oussedik N, Poujois A. New tools for Wilson’s disease diagnosis: exchangeablecopper fractio. Ann Transl Med 2019; 7(Suppl 2): S70. doi: 10.21037/atm.2019
- WHO Guidelines Review Committee, Nutrition and Food Safety (NFS). WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations [Internet]. Geneva: World Health Organization 2020. [cited 2024 Jan 15]. Available at:
https://www.who.int/publications/i/item/9789240000124 . PMID: 33909381 - Lossow K, Schwarz M, Kipp AP. Are trace element concentrations suitable biomarkers for the diagnosis of cancer? Redox Biol 2021; 42: 101900. doi: 10.1016/j.redox.2021.101900
- Chen F, Han B, Meng Y, Han Y, Liu B, Zhang B, et al. Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer. Aging 2021; 13: 20438–67. doi: 10.18632/aging.203427
- Balter V, Nogueira da Costa A, Bondanese VP, Jaouen K, Lamboux A, et al. Natural variations of copper and sulfur stable isotopes in blood of hepatocellular carcinoma patients. Proc Natl Acad Sci U S A 2015; 112: 982–5. doi: 10.1073/pnas.1415151112
- Hastuti AAMB, Costas-Rodríguez M, Matsunaga A, Ichinose T, Hagiwara S, Shimura M, et al. Cu and Zn isotope ratio variations in plasma for survival prediction in hematological malignancy cases. Sci Rep 2020; 10: 16389. doi: 10.1038/s41598-020-71764-7
- Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, et al. Connecting copper and cancer: from transition metal signaling to metalloplasia. Nat Rev Cancer 2022; 22: 102–13. doi: 10.1038/s41568-021-00417-2
- Wang J, Zhao H, Xu Z, Cheng X. Zinc dysregulation in cancers and its potential as a therapeutic target. Cancer Biol Med 2020; 17: 612–25. doi: 10.20892/j.issn.2095-3941.2020.0106
- Krężel A, Maret W. The biological inorganic chemistry of zinc ions. Arch Biochem Biophys 2016; 611: 3–19. doi: 10.1016/j.abb.2016.04.010
- Infusino I, Valente C, Dolci A, Panteghini M. Standardization of ceruloplasmin measurements is still an issue despite the availability of a common reference material. Anal Bioanal Chem 2009; 397: 521–5. doi: 10.1007/s00216-009-3248-0
- Quarles CD, Macke M Jr, Michalke B, Zischka H, Karst U, Sullivan P, et al. LC-ICP-MS method for the determination of “extractable copper” in serum. Metallomics 2020; 12: 1348–55. doi: 10.1039/d0mt00132e
- Neselioglu S, Ergin M, Erel O. A new kinetic, automated assay to determine the ferroxidase activity of ceruloplasmin. Anal Sci 2017; 33: 1339–44. doi: 10.2116/analsci.33.1339
- Solovyev N, Ala A, Schilsky M, Mills C, Willis, K, Harrington C F. Biomedical copper speciation in relation to Wilson’s disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma-mass spectrometry. Anal. Chim Acta 2020; 1098: 27–36. doi: 10.1016/j.aca.2019.11.033
- Bernevic B, El-Khatib AH, Jakubowski N, Weller MG. Online immunocapture ICP-MS for the determination of the metalloprotein ceruloplasmin in human serum. BMC Res Notes 2018; 11: doi:10.1186/s13104-018-3324-7
- Marković K, Milačič R, Vidmar J, Marković S, Uršič K, Nikšić Žakelj M, et al. Monolithic chromatography on conjoint liquid chromatography columns for speciation of platinum-based chemotherapeutics in serum of cancer patients. J Trace Elem Med Biol 2020; 57: 28–39. doi: 10.1016/j.jtemb.2019.09.011
- Marković K, Milačič R, Marković S, Kladnik J, Turel I, Ščančar J. Binding kinetics of ruthenium pyrithione chemotherapeutic candidates to human serum proteins studied by HPLC-ICP-MS. Molecules 2020; 25: 1512–3. doi: cules25071512
- Martinčič A, Čemažar M, Serša G, Kovač V, Milačič R, Ščančar J. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection. Talanta 2013; 116: 141–8, doi: 10.1016/j.talanta.2013.05.016
- Martinčič A, Milačič R, Vidmar J, Turel I, Keppler BK, Ščančar J. New method for the speciation of Ru-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks. J Chromatogr A 2014; 1371: 168–76. doi: 10.1016/j.chroma.2014.10.054
- Marković K, Cemazar M, Sersa G, Milačič R, Ščančar J. Speciation of copper in human serum using conjoint liquid chromatography on short-bed monolithic disks with UV and post column ID-ICP-MS detection. J Anal At Spectrom 2022; 37: 1675–86. doi: 10.1039/D2JA00161F
- Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 2016; 62:132–7. doi: 10.1016/j.ejca.2016.03.081
- Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143–e52. doi: 10.1016/S1470-2045(17)30074-8. Erratum in: Lancet Oncol 2019; 20: e242.
- National Cancer Institute (NCI). NCI common terminology criteria for adverse events (CTCAE). Version 5.0.2021. [cited 2024 Feb 18]. Available at:
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf